TY - JOUR T1 - High seroprevalence of SARS-CoV-2 antibodies among people living in precarious situations in Ile de France JF - medRxiv DO - 10.1101/2020.10.07.20207795 SP - 2020.10.07.20207795 AU - Thomas Roederer AU - Bastien Mollo AU - Charline Vincent AU - Birgit Nikolay AU - Augusto Llosa AU - Robin Nesbitt AU - Jessica Vanhomwegen AU - Thierry Rose AU - François Anna AU - Corinne Torre AU - Emilie Fourrey AU - Erica Simons AU - Sophie Goyard AU - Yves Janin AU - Pierre Charneau AU - Oxana Vratskikh AU - Anneliese Coury AU - Stefan Vanel AU - Pierre Mendiharat AU - Klaudia Porten AU - William Hennequin AU - Clair Mills AU - Francisco Luquero Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/09/2020.10.07.20207795.abstract N2 - Background A nationwide lockdown was implemented in France on 17 March 2020 to control the COVID-19 pandemic. People living in precarious conditions were relocated by the authorities to emergency shelters, hotels and large venues. Médecins sans Frontières (MSF) then intervened to provide medical care in several of these locations in Paris and in Seine-Saint-Denis, one of its suburbs, between March and June 2020. A seroprevalence survey was conducted to assess the level of exposure to COVID-19 among the population living in the sites. To our knowledge, this is the first assessment of the impact of the pandemic on populations living in insecure conditions in Europe.Methods We conducted a cross-sectional seroprevalence study in the food distribution sites, emergency shelters and workers residences supported by MSF in Paris and Seine-Saint-Denis, to determine the extent of COVID-19 exposure as determined by SARS-CoV2 antibody seropositivity. The detection of SARS-COV2 antibodies in serum was performed at the Institut Pasteur of Paris using two LuLISA (Luciferase-Linked Immunosorbent Assay) assays and a Pseudo Neutralization Test. A questionnaire covering sociodemographic characteristics, living conditions, adherence to sanitary recommendations and symptom manifestations was also completed. We describe here the seroprevalence site by site and identify the risk factors for seropositivity using a multivariable logistic regression model with site random effects. We also investigated associations between seropositivity and symptoms eventually reported.Findings Overall, 426/818 individuals tested positive in the 14 sites investigated. Seroprevalence varied significantly with the type of site (chi2 p<0.001). It was highest at 88.7% (95%CI 81.8-93.2) among individuals living in workers’ residences, followed by 50.5% (95%CI 46.3-54.7) in emergency shelters and 27.8 % (95%CI 20.8-35.7) among individuals recruited from the food distribution sites. Seroprevalence also varied significantly between sites of the same type. Among other risk factors, the odds for seropositivity were higher among individuals living in crowded sites (medium: adj. OR 2.7, 95%CI 1.5-5.1, p=0.001; high: adj. OR 3.4, 95%CI 1.7-6.9, p<0.001) compared with individuals from low crowding sites and among those who reported transit accommodation in a gymnasium before the lockdown (adj. OR 3.1, 95%CI 1.2-8.1, p=0.023). More than two-thirds of the seropositive individuals (68.3%; 95%CI 64.2-72.2) did not report any symptoms during the recall period.Interpretation The results demonstrate rather high exposure to SARS-COV-2 with important variations between study sites. Living in crowded conditions was identified as the most important explanatory factor for differences in levels of exposure. This study describes the key factors which determine the risk of exposure and illustrates the importance of identifying populations at high risk of exposure in order to orient and adapt prevention and control strategies to their specific needs.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialStudy was registered in France only, it is not a clinical trial, but an epidemiological survey in population.Funding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This protocol was approved by the MSF ethics review board on 18 June 2020, reference number 2044) and by the Comite de Protection des Personnes (CPP), Ile de France, Paris XI, approved 19 June 2020 (reference number 20050-62628).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDatabases used for the analyses are available upon request to the corresponding author. ER -